A prospective study of the forearm bone density of users of etonorgestrel- and levonorgestrel-releasing contraceptive implants

Human Reproduction

Volumn 21, Issue 2, 2006, Pages 466-470

  Bahamondes, Luis ^a,b   Monteiro Dantas, Cecilia ^a   Espejo Arce, Ximena ^a   dos Santos Fernandes, Arlete M ^a   Lui Filho, Jeffrey F ^a   Perrotti, Marcos ^a   Petta, Carlos A ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b NONE   (Brazil)

Author keywords

Bone mineral density; Contraceptive implants; Etonorgestrel; Levonorgestrel

Indexed keywords

CONTRACEPTIVE AGENT; ETONOGESTREL; LEVONORGESTREL;

ADULT; AGE DISTRIBUTION; ANTHROPOMETRY; ARTICLE; BODY MASS; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICAL BONE; DEMOGRAPHY; DRUG RELEASE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOREARM; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE LINEAR REGRESSION ANALYSIS; PROSPECTIVE STUDY; RADIUS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; ULNA;

EID: 31544479793     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/dei358     Document Type: Article

References (40)

1. Armitage P (1971) Statistical Methods in Medical Research, 3rd edn. A Halsted Press Book, John Wiley and Sons, New York.
2. Bagger YZ, Tanko LB, Alexandersen P, Hansen HB, Mollgaard A, Ravn P, Qvist P, Kanis JA and Christiansen C (2004) Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: The PERF study. Bone 34,728-735.
3. Bahamondes L, Perrotti M, Castro S, Faúndes D, Petta C and Bedone A (1999) Forearm bone density in users of Depo-Provera as a contraceptive method. Fertil Steril 71,849-852.
4. Bahamondes L, Trevisan M, Andrade L, Marchi NM, Castro S, Diaz J and Faúndes A (2000) The effect upon the human vaginal histology of the long-term use of the injectable contraceptive Depo-Provera. Contraception 62,23-27.
5. Banks E, Berrington A and Casabonne D (2001) Overview of the relationship between use of progestogen-only contraceptives and bone mineral density. Br J Obstet Gynaecol 108,1214-1221.
6. Beerthuizen R, van Beek A, Massai R, Makarainen L, Hout J and Bennink HC (2000) Bone mineral density during long-term use of the progestagen contraceptive implant Implanon compared to a non-hormonal method of contraception. Hum Reprod 15,118-122.
7. Cefalu CA (2004) Is bone mineral density predictive of fracture risk reduction? Curr Med Res Opin 20,341-349.
8. Cromer BA, Blair JM, Mahan JD, Zibners L and Naumovski Z (1996) A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatr 129,671-676.
9. Croxatto HB, Diaz S, Pavez M and Brandeis A (1988) Estradiol plasma levels during long-term treatment with Norplant subdermal implants. Contraception 38,465-475.
10. Croxatto HB (2002) Progestin implants for female contraception. Contraception 65,21-27.
11. Croxatto HB, Urbancsek J, Massai R, Coelingh BH and van Beek A (1999) A multicentre efficacy and safety study of the single contraceptive implant Implanon. Hum Reprod 14,976-981.
12. Cundy T, Evans MC, Roberts H, Wattie D, Ames R and Reid IR (1991) Bone density in women receiving depot medroxyprogesterone acetate for contraception. Br Med J 303,13-16.
13. Cundy T, Cornish J, Evans M, Roberts H, Elder H and Reid I (1998) Spinal bone density in women using depot medroxyprogesterone contraception. Obstet Gynecol 92,569-573.
14. Curtis KM (2002) Safety of implantable contraceptives for women: Data from observational studies. Contraception 65,85-96.
15. Di X, Li Y, Zhang C, Jiang J and Gu S (1999) Effects of levonorgestrel-releasing subdermal contraceptive implants on bone density and bone metabolism. Contraception 60,161-166.
16. Diaz S, Reyes MV, Zepeda A, Gonzalez GB, Lopez JM, Campino C and Croxatto HB (1999) Norplant implants and progesterone vaginal rings do not affect maternal bone turnover and density during lactation and after weaning. Hum Reprod 14,2499-2505.
17. Gbolade B, Ellis S, Murby B, Randall S and Kirkman R (1998) Bone density in long-term users of depot medroxyprogesterone acetate. Br J Obstet Gynaecol 105,790-794.
18. Kanis JA, Johnell O, Oden A, Johansson H, De Laet C, Eisman JA, Fujiwara S, Kroger H, McCloskey EV, Mellstrom D et al. (2005a) Smoking and fracture risk: A meta-analysis. Osteoporos Int 16,155-162.
19. Kanis JA, Johansson H, Johnell O, Oden A, De Laet C, Eisman JA, Pols H and Tenenhouse A (2005b) Alcohol intake as a risk factor for fracture. Osteoporos Int 16,737-742.
20. Karlsson C, Obrant KJ and Karlsson M (2001) Pregnancy and lactation confer reversible bone loss in humans. Osteoporos Int 12,828-834.
21. Lappe JM, Stegman MR and Recker RR (2001) The impact of lifestyle factors on stress fractures in female Army recruits. Osteoporos Int 12,35-42.
22. Makarainen L, van Beek A, Tuomivaara L, Asplund B and Coelingh Bennink H (1998) Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant. Fertil Steril 69,714-721.
23. Marshall D, Johnell O and Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Br Med J 312,1254-1259.
24. Meirik O, Fraser IS, d'Arcangues C and the WHO consultation on implantable contraception for women (2003) Implantable contraceptives for women. Hum Reprod Update 9,49-59.
25. Naessen T, Olsson SE and Gudmundson J (1995) Differential effects on bone density of progestogen-only methods for contraception in premenopausal women. Contraception 52,35-39.
26. Orr-Walker BJ, Evans MC, Ames RW, Clearwater JM, Cundy T and Reid IR (1998) The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women. Clin Endocrinol (Oxf) 49,615-618.
27. Perrotti M, Bahamondes L, Petta C and Castro S (2001) Forearm bone density in long-term users of oral combined contraceptives and depot medroxyprogesterone acetate. Fertil Steril 76,469-473.
28. Petitti DB, Piaggio G, Metha S, Cravioto MC and Meirik O (2000) Steroid hormone contraception and bone mineral density: A cross-sectional study in an international population. Obstet Gynecol 95,736-744.
29. Pocock SJ (1987) Clinical Trials: A Practical Approach. John Wiley and Sons, Chichester.
30. Recker RR, Davies KM, Hinders SM, Heaney RP, Stegman MR and Kimmel DB (1992) Bone gain in young adult women. J Am Med Assoc 17,2403-2408.
31. Riggs BL and Melton JL III (1986) Involutional osteoporosis. N Engl J Med 314,1676-1686.
32. Schonau E. (2004) The peak bone mass concept: Is it still relevant? Pediatr Nephrol 19,825-831.
33. Schonau E (2004) The peak bone mass concept: Is it still relevant? Pediatr Nephrol 19,825-831.
34. Smith R (2003) Medical journals and pharmaceutical companies: Uneasy bedfellows. Br Med J 326,1202-1205.
35. Tang OS, Tang G, Yip P, Li B and Fan S (1999) Long-term depotmedroxyprogesterone acetate and bone mineral density. Contraception 59, 25-29.
36. Taneepanichskul S, Intaraprasert S, Theppisai U and Chaturachinda K (1997) Bone mineral density during long-term treatment with Norplant implants and depot medroxyprogesterone acetate. A cross-sectional study of Thai women. Contraception 56,153-155.
37. United States Food and Drug Administration (2004) Talk Paper Black Box Warning Added Concerning Long-Term Use of Depo-Provera Contraceptive Injection. November 17.
38. World Health Organization (1994) Assessment of Fracture Risk and its Application to Screening for Post-menopausal Osteoporosis: Report of a WHO Study Group. WHO, Geneva (WHO technical report series 843).
39. World Health Organization (2004) Medical eligibility criteria for contraceptive use 3rd ed. Geneva.
40. World Health Organization (2005) WHO Statement on hormonal contraception and bone health. July.